Abnova Taiwan Corp

Abnova (Taiwan) Corporation is involved in the research, development, manufacturing, and sales of monoclonal and polyclonal antibodies, proteins, medical diagnostic instruments, and testing reagents. Its product portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, antibody pairs/kits, antibody arrays, polyclonal antibodies, beads/dyes, in situ hybridization products, systems, and automation. The company also offers MaxPab, Nano, DNAxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. Additionally, it provides integrated solutions and services such as gene synthesis and cytogenetics; peptide services, protein expression, and conjugations; antibody production and scale-up; assay development; circulating tumor cell and DNA; germline genetic DNA; and FFPE tumor tissue DNA services. It serves academic and research institutions and pharmaceutical factories. Founded in 2002, Abnova (Taiwan) Corporation is headquartered in Taipei, Taiwan.